A141 DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90MG Q8W IN PHASE III PROGRAM

od Naessens, D, Johanns, J, Gasink, C
Wydane w J Can Assoc Gastroenterol (2018)

A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY

od Sands, B E, Gasink, C, Jacobstein, D, Gao, L, Johanns, J, Szapary, P, Colombel, J F, Targan, S, Ghosh, S, Sandborn, W
Wydane w J Can Assoc Gastroenterol (2018)

A80 ENDOSCOPIC HEALING WITH USTEKINUMAB IN CROHN’S DISEASE: THE UNITI ENDOSCOPY SUB-STUDY

od Feagan, B G, Sandborn, W, Gasink, C, Chan, D, Lang, Y, Pollack, P, Hanauer, S, Wolf, D, Jacobstein, D, Johanns, J, Szapary, P, Rutgeerts, P
Wydane w J Can Assoc Gastroenterol (2018)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

od Sandborn, W. J., Rutgeerts, P., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Sands, B. E., Hanauer, S. B., Targan, S., Ghosh, S., de Villiers, W. J. S., Colombel, J.‐F., Feagan, B. G.
Wydane w Aliment Pharmacol Ther (2018)

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

od Rutgeerts, P., Feagan, B. G., Marano, C. W., Padgett, L., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Zhang, H., Colombel, J.‐F., Reinisch, W., Gibson, P. R., Sandborn, W. J.
Wydane w Aliment Pharmacol Ther (2015)